date:Aug 17, 2012
glucosamine and maintenance of normal joint cartilage.
The NDA rejected arguments raised by Merck relating to healthy versus diseased study populations; bioavailability; and biomarkers and demonstration of physical effects.
Merck was not available for comment about the significance of the NDA verdict at the time of publication.
Grounds for rejection
Of bioavailability concerns, the NDA stated that, while the available evidence shows that some dietary glucosamine is taken up into blood and s